Dalteparin: Difference between revisions
Jump to navigation
Jump to search
Matt Pijoan (talk | contribs) m (Protected "Dalteparin": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite))) |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | |||
{{Dalteparin}} | |||
{{CMG}}; {{AE}} {{PB}} | |||
'''''For patient information, click [[Dalteparin (patient information)|here]]'''''. | |||
== | ==Overview== | ||
'''Dalteparin''' is a [[low molecular weight heparin]]. It is marketed as '''Fragmin''' by [[Pfizer|Pfizer Inc]]. Like other low molecular weight heparins, dalteparin is used for prophylaxis or treatment of [[deep vein thrombosis]] and [[pulmonary embolism]]. | |||
[[ | |||
[[ | |||
[[ | |||
[[ | |||
The CLOT study, published in 2003, showed that in patients with malignancy and acute [[venous thromboembolism]], dalteparin was more effective than [[warfarin]] in reducing the risk of recurrent embolic events.<ref>{{cite journal | author=Lee AY, Levine MN, Baker RI, Bowden C, [[Ajay Kakkar, Baron Kakkar|Kakkar AK]], Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent M | title=Low-molecular-weight heparin versus a Coumadin for the prevention of recurrent venous thromboembolism in patients with cancer | journal=N Engl J Med | year=2003 | pages=146–53 | volume=349 | issue=2 | pmid=12853587 | doi=10.1056/NEJMoa025313}}</ref> Dalteparin is not superior to [[unfractionated heparin]] in preventing blood clots.<ref>{{cite journal|author=The PROTECT Investigators for the Canadian Critical Care Trials Group and the Australian and New Zealand Intensive Care Society Clinical Trials Group|title=Dalteparin versus unfractionated heparin in critically ill patients|year=2011|doi=10.1056/NEJMoa1014475}}</ref> | |||
[ | |||
< | |||
[[ | |||
< | |||
== | Heparins are cleared by the kidneys, but studies have shown that dalteparin does not accumulate even if kidney function is reduced.<ref>{{cite journal | author=Douketis J, Cook D, Meade M ''et al.'' | title=Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin | journal=Arch Intern Med | year=2008 | volume=168 | issue=16 | pmid=18779469 | pages=1805–1812 | doi=10.1001/archinte.168.16.1805}}</ref> | ||
==Category== | |||
< | |||
Anticoagulants:Heprin group | |||
==US Brand Names== | |||
FRAGMIN<sup>®</sup> | |||
==FDA Package Insert== | |||
< | |||
< | |||
'''| [[Dalteparin indications and usage|Indications and Usage]]''' | |||
[ | '''| [[Dalteparin dosage and administration|Dosage and Administration]]''' | ||
'''| [[Dalteparin dosage forms and strengths|Dosage Forms and Strengths]]''' | |||
'''| [[Dalteparin contraindications|Contraindications]]''' | |||
'''| [[Dalteparin warnings|Warnings and Precautions]]''' | |||
'''| [[Dalteparin adverse reactions|Adverse Reactions]]''' | |||
'''| [[Dalteparin drug interactions|Drug Interactions]]''' | |||
'''| [[Dalteparin use in specific populations|Use in Specific Populations]]''' | |||
'''| [[Dalteparin overdosage|Overdosage]]''' | |||
'''| [[Dalteparin description|Description]]''' | |||
'''| [[Dalteparin clinical pharmacology|Clinical Pharmacology]]''' | |||
'''| [[Dalteparin nonclinical toxicology|Nonclinical Toxicology]]''' | |||
'''| [[Dalteparin clinical studies|Clinical Studies]]''' | |||
'''| [[Dalteparin how supplied storage and handling|How Supplied/Storage and Handling]]''' | |||
'''| [[Dalteparin patient counseling information|Patient Counseling Information]]''' | |||
'''| [[Dalteparin labels and packages|Labels and Packages]]''' | |||
==Mechanism of Action== | |||
[[Category:Drugs]] | ==References== | ||
{{Reflist|2}} | |||
[[Category:Heprin group]] | |||
[[Category:Anticoagulants]] | |||
[[Category:Cardiovascular Drugs]] | |||
{{WikiDoc Help Menu}} | |||
{{WikiDoc Sources}} | |||
Revision as of 19:12, 31 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Pratik Bahekar, MBBS [2]
For patient information, click here.
Overview
Dalteparin is a low molecular weight heparin. It is marketed as Fragmin by Pfizer Inc. Like other low molecular weight heparins, dalteparin is used for prophylaxis or treatment of deep vein thrombosis and pulmonary embolism.
The CLOT study, published in 2003, showed that in patients with malignancy and acute venous thromboembolism, dalteparin was more effective than warfarin in reducing the risk of recurrent embolic events.[1] Dalteparin is not superior to unfractionated heparin in preventing blood clots.[2]
Heparins are cleared by the kidneys, but studies have shown that dalteparin does not accumulate even if kidney function is reduced.[3]
Category
Anticoagulants:Heprin group
US Brand Names
FRAGMIN®
FDA Package Insert
| Indications and Usage | Dosage and Administration | Dosage Forms and Strengths | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Use in Specific Populations | Overdosage | Description | Clinical Pharmacology | Nonclinical Toxicology | Clinical Studies | How Supplied/Storage and Handling | Patient Counseling Information | Labels and Packages
Mechanism of Action
References
- ↑ Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent M (2003). "Low-molecular-weight heparin versus a Coumadin for the prevention of recurrent venous thromboembolism in patients with cancer". N Engl J Med. 349 (2): 146–53. doi:10.1056/NEJMoa025313. PMID 12853587.
- ↑ The PROTECT Investigators for the Canadian Critical Care Trials Group and the Australian and New Zealand Intensive Care Society Clinical Trials Group (2011). "Dalteparin versus unfractionated heparin in critically ill patients". doi:10.1056/NEJMoa1014475.
- ↑ Douketis J, Cook D, Meade M; et al. (2008). "Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin". Arch Intern Med. 168 (16): 1805–1812. doi:10.1001/archinte.168.16.1805. PMID 18779469.